Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs

NCT04077957 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Ankylosing Spondylitis
Spondyloarthritis

Interventions

DRUG: Methotrexate
DRUG: Sulfasalazine
DRUG: Hydroxychloroquine
DRUG: Etanercept (50mg per week, for 4 weeks)
DRUG: Etanercept (50mg per week, for 2 weeks)
DRUG: Etanercept (50mg per week)

Sponsor

Nanfang Hospital, Southern Medical University